ArticleJTO clinical and research reports2023

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors.

Xiaorong Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.